Showing 5671-5680 of 8552 results for "".
- Long-Term Ixekizumab Use Not Linked to Increased Cancer Risk: Analysishttps://practicaldermatology.com/news/long-term-ixekizumab-use-not-linked-to-increased-cancer-risk/2475704/Long-term treatment with ixekizumab (IXE) for psoriasis, psoriatic arthritis, and axial spondyloarthritis was not associated with increased risk of malignant neoplasms, according to a new analysis of pooled data from 25 randomized clinical trials.
- LEQSELVI™ Launches in U.S. as Oral Treatment for Severe Alopecia Areatahttps://practicaldermatology.com/news/leqselvitm-launches-in-us-as-oral-treatment-for-severe-alopecia-areata/2475680/Sun Pharmaceutical Industries Ltd. announced the U.S. commercial availability of LEQSELVI™ (deuruxolitinib), an oral Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata, according to a press release from the manufacturer.
- OSkin Study: Genetic Risk and Nevus Count Stronger Predictors for NAMhttps://practicaldermatology.com/news/genetic-risk-and-nevus-count-stronger-predictors-for-nam-study-finds/2475635/High nevus density and polygenic susceptibility are more strongly associated with nevus-associated melanoma (NAM) than with de novo melanoma, according to results from a new large-scale, population-based cohort study. The QSk
- Upcoming Skin Cancer Champions Webinar Addresses Impact of AIhttps://practicaldermatology.com/news/Upcoming-Skin-Cancer-Champions-Webinar-Addresses-Impact-AI/2475627/Veronica Rotemberg, MD, PhD, will host a free webinar on the future of non-melanoma skin cancer care August 5 at 1:00 PM ET, Skin Cancer Champions announced. Dr. Rotemberg, Director of Dermatology Imaging Informatics for Memorial Sloan Kettering Cancer Center, will present “The Future of S
- Positive Early Results in Tralokinumab Trial for AD on Handshttps://practicaldermatology.com/news/Positive-Early-Results-Tralokinumab-Trial-AD-Hands/2475575/A trial evaluating tralokinumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) on the hands, who are candidates for systemic therapy, met the primary endpoint and all secondary endpoints with a statistically significant improvement in AD on the hands after 16 weeks of
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the
- VISIBLE: Guselkumab Provides Scalp Psoriasis Relief in Diverse Skin Toneshttps://practicaldermatology.com/news/visible-guselkumab-provides-scalp-psoriasis-relief-in-diverse-skin-tones/2475455/Guselkumab 100 mg demonstrated efficacy and sustained improvement through 48 weeks in a cohort of adults with moderate to severe scalp psoriasis and skin of color, new research suggests. In the B cohort of the phase 3b, rand
- Hands On: Practical Tips for Diagnosing and Treating Chronic Hand Eczemahttps://practicaldermatology.com/news/hands-on-practical-tips-for-diagnosing-and-treating-chronic-hand-eczema/2475415/Despite its small body surface area involvement, chronic hand eczema (CHE) represents a significant dermatologic and socioeconomic burden. In a recent session on chronic hand eczema (CHE) Socity of Dermatology Physician Associates (SDPA) 2025 Summer Conference given by Adam Friedman, MD, FAAD, he
- ZORYVE Cream 0.15% Gets AAD Endorsement for Atopic Dermatitishttps://practicaldermatology.com/news/zoryve-cream-015-gets-aad-endorsement-for-atopic-dermatitis/2475411/The American Academy of Dermatology (AAD) has issued a strong recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adult patients with mild to moderate atopic dermatitis (AD), according to updated guidelines released June 26.